Uterine adenosarcomas are mesenchymal neoplasms

Journal of Pathology

Volumn 238, Issue 3, 2016, Pages 381-388

  Piscuoglio, Salvatore ^a   Burke, Kathleen A ^a   Ng, Charlotte K Y ^a   Papanastasiou, Anastasios D ^a,b   Geyer, Felipe C ^a,c   Macedo, Gabriel S ^a   Martelotto, Luciano G ^a   De Bruijn, Ino ^a   De Filippo, Maria R ^a   Schultheis, Anne M ^a   Ioris, Rafael A ^a   Levine, Douglas A ^a   Soslow, Robert A ^a   Rubin, Brian P ^d   Reis Filho, Jorge S ^a   Weigelt, Britta ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF PATRAS   (Greece)

^c HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

FISH; massively parallel sequencing; RNA sequencing; uterine adenosarcoma

Indexed keywords

MITOCHONDRIAL DNA; RNA; TUMOR PROTEIN;

ADENOSARCOMA; ARTICLE; CDK4 GENE; CLINICAL ARTICLE; CONTROLLED STUDY; DICER1 GENE; DNA SEQUENCE; FEMALE; FGFR2 GENE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE AMPLIFICATION; HISTOPATHOLOGY; HMGA2 GENE; HUMAN; HUMAN TISSUE; KMT2C GENE; LASER CAPTURE MICRODISSECTION; MASSIVELY PARALLEL SEQUENCING; MDM2 GENE; MUTATOR GENE; PRIORITY JOURNAL; RNA SEQUENCE; SEQUENCE ANALYSIS; SOMATIC MUTATION; TERT GENE; TUMOR DIFFERENTIATION; TUMOR GENE; UTERINE ADENOSARCOMA; UTERUS SARCOMA; WHOLE EXOME SEQUENCING; GENE FUSION; GENETICS; HIGH THROUGHPUT SEQUENCING; IN SITU HYBRIDIZATION; MUTATION; PATHOLOGY; UTERUS CANCER;

ADENOSARCOMA; FEMALE; GENE FUSION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IN SITU HYBRIDIZATION; MUTATION; NEOPLASM PROTEINS; SEQUENCE ANALYSIS, RNA; UTERINE NEOPLASMS;

EID: 84956763981     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4675     Document Type: Article

References (49)

1. Clement PB, Young RH., Mesenchymal and mixed epithelial-mesenchymal tumors of the uterine corpus and cervix. In Atlas of Gynecologic Surgical Pathology, 3rd edn. Saunders/Elsevier: Philadelphia, PA, 2014; 218-270.
2. Wells M, Oliva E, Palacios J, et al., Mixed epithelial and mesenchymal tumours. In WHO Classification of Tumours of Female Reproductive Organs, Kurman RJ, Carcangiu ML, Herrington CS, et al (eds). IARC Press: Lyon, 2014; 148-151.
3. McCluggage WG,. Mullerian adenosarcoma of the female genital tract. Adv Anat Pathol 2010; 17: 122-129.
4. Carroll A, Ramirez PT, Westin SN, et al., Uterine adenosarcoma: an analysis on management, outcomes, and risk factors for recurrence. Gynecol Oncol 2014; 135: 455-461.
5. Howitt BE, Sholl LM, Dal Cin P, et al., Targeted genomic analysis of Mullerian adenosarcoma. J Pathol 2015; 235: 37-49.
6. Tan PH, Tse G, Lee A, et al., Fibroepithelial tumours. In WHO Classification of Tumours of the Breast, 4th edn, Lakhani SR, Ellis IO, Schnitt SJ, et al. (eds). IARC Press: Lyon, 2012; 141-147.
7. Lim WK, Ong CK, Tan J, et al., Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma. Nat Genet 2014; 46: 877-880.
8. Yoshida M, Sekine S, Ogawa R, et al., Frequent MED12 mutations in phyllodes tumours of the breast. Br J Cancer 2015; 112: 1703-1708.
9. Kuijper A, Buerger H, Simon R, et al., Analysis of the progression of fibroepithelial tumours of the breast by PCR-based clonality assay. J Pathol 2002; 197: 575-581.
10. Weinreb I, Piscuoglio S, Martelotto LG, et al., Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. Nat Genet 2014; 46: 1166-1169.
11. Cheng DT, Mitchell TN, Zehir A, et al., Memorial Sloan-Kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn 2015; 17: 251-264.
12. Natrajan R, Wilkerson PM, Marchio C, et al., Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. J Pathol 2014; 232: 553-565.
13. Dickson MA, Tap WD, Keohan ML, et al., Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol 2013; 31: 2024-2028.
14. Ho AS, Kannan K, Roy DM, et al., The mutational landscape of adenoid cystic carcinoma. Nat Genet 2013; 45: 791-798.
15. Masuda S, Kadowaki T, Kumaki N, et al., Analysis of gene alterations of mitochondrial DNA D-loop regions to determine breast cancer clonality. Br J Cancer 2012; 107: 2016-2023.
16. McPherson A, Hormozdiari F, Zayed A, et al., deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput Biol 2011; 7: e1001138.
17. Iyer MK, Chinnaiyan AM, Maher CA., ChimeraScan: a tool for identifying chimeric transcription in sequencing data. Bioinformatics (Oxford, England) 2011; 27: 2903-2904.
18. Mosquera JM, Sboner A, Zhang L, et al., Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma. Genes Chromosomes Cancer 2013; 52: 538-550.
19. Esteyries S, Perot C, Adelaide J, et al., NCOA3, a new fusion partner for MOZ/MYST3 in M5 acute myeloid leukemia. Leukemia 2008; 22: 663-665.
20. Jones S, Stransky N, McCord CL, et al., Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes. Nat Commun 2014; 5: 5006.
21. Martelotto LG, De Filippo MR, Ng CK, et al., Genomic landscape of adenoid cystic carcinoma of the breast. J Pathol 2015; DOI: 10.1002/path.4573.
22. Guerini-Rocco E, Hodi Z, Piscuoglio S, et al., The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study. J Pathol 2015; DOI: 10.1002/path.4566.
23. Li H, Durbin R,. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754-1760.
24. McKenna A, Hanna M, Banks E, et al., The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010; 20: 1297-1303.
25. Cibulskis K, Lawrence MS, Carter SL, et al., Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 2013; 31: 213-219.
26. Koboldt DC, Zhang Q, Larson DE, et al., VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 2012; 22: 568-576.
27. Saunders CT, Wong WS, Swamy S, et al., Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics 2012; 28: 1811-1817.
28. De Mattos-Arruda L, Weigelt B, Cortes J, et al., Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof of principle. Ann Oncol 2014; 25: 1729-1735.
29. Schwarz JM, Rodelsperger C, Schuelke M, et al., MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods 2010; 7: 575-576.
30. Carter H, Chen S, Isik L, et al., Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res 2009; 69: 6660-6667.
31. Martelotto LG, Ng C, De Filippo MR, et al., Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations. Genome Biol 2014; 15: 484.
32. Shihab HA, Gough J, Cooper DN, et al., Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden Markov models. Hum Mutat 2013; 34: 57-65.
33. Kandoth C, McLellan MD, Vandin F, et al., Mutational landscape and significance across 12 major cancer types. Nature 2013; 502: 333-339.
34. Futreal PA, Coin L, Marshall M, et al., A census of human cancer genes. Nat Rev Cancer 2004; 4: 177-183.
35. Lawrence MS, Stojanov P, Mermel CH, et al., Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014; 505: 495-501.
36. Carter SL, Cibulskis K, Helman E, et al., Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol 2012; 30: 413-421.
37. Landau DA, Carter SL, Stojanov P, et al., Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013; 152: 714-726.
38. Ronglai S, Seshan V,. FACETS: Fraction and allele-specific copy number estimates from tumor sequencing. Memorial Sloan-Kettering Cancer Center, Department of Epidemiology and Biostatistics Working Paper Series, 2015.
39. Curtis C, Shah SP, Chin SF, et al., The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature 2012; 486: 346-352.
40. Kohsaka S, Shukla N, Ameur N, et al., A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. Nat Genet 2014; 46: 595-600.
41. Cancer Genome Atlas N,. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
42. Shugay M, Ortiz de Mendibil I, Vizmanos JL, et al., Oncofuse: a computational framework for the prediction of the oncogenic potential of gene fusions. Bioinformatics 2013; 29: 2539-2546.
43. Piscuoglio S, Ng CK, Martelotto LG, et al., Integrative genomic and transcriptomic characterization of papillary carcinomas of the breast. Mol Oncol 2014; 8: 1588-1602.
44. Li H, Handsaker B, Wysoker A, et al., The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009; 25: 2078-2079.
45. Tamura K, Dudley J, Nei M, et al., MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007; 24: 1596-1599.
46. Tognon C, Knezevich SR, Huntsman D, et al., Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2002; 2: 367-376.
47. Weigelt B, Geyer FC, Reis-Filho JS,. Histological types of breast cancer: how special are they? Mol Oncol 2010; 4: 192-208.
48. Weigelt B, Reis-Filho JS,. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol 2009; 6: 718-730.
49. Wetterskog D, Lopez-Garcia MA, Lambros MB, et al., Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. J Pathol 2012; 226: 84-96.